Akebia Therapeutics
AKBA
153 hedge funds and large institutions have $532M invested in Akebia Therapeutics in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 18 closing their positions.
199% more call options, than puts
Call options by funds: $4.36M | Put options by funds: $1.46M
59% more capital invested
Capital invested by funds: $334M → $532M (+$198M)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
2% more funds holding
Funds holding: 150 → 153 (+3)
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0.88% less ownership
Funds ownership: 71.7% → 70.83% (-0.88%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.5M |
| 2 |
Millennium Management
New York
|
+$2.96M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.78M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.55M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$23.3M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.81M |
| 3 |
BlackRock
New York
|
-$1.52M |
| 4 |
Citigroup
New York
|
-$1.22M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.18M |
AKBA Hedge Fund Activity: Q4 2019 in Review
153 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2019, worth a combined $532M — up 59% from $334M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AKBA positions and 18 closed out — a net gain of 5 holders — while 50 added to existing stakes and 46 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.5M. The largest seller was Baupost Group, cutting an estimated $23.3M.
- 153 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2019, up from 150 in Q3 2019.
- Funds reported $532M of Akebia Therapeutics stock for Q4 2019, up 59% quarter-over-quarter.
- 23 funds opened new Akebia Therapeutics positions in Q4 2019 and 18 closed out, a net change of +5 holders.
- The largest Akebia Therapeutics buyer in Q4 2019 was Nantahala Capital Management, an estimated $4.5M added.
- The largest Akebia Therapeutics seller in Q4 2019 was Baupost Group, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2019.